Alpha 2.0
Login Register
» Authors » Simon Eng

Simon Eng

Explore the profile of Simon Eng including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 18
Followers 0
Related Specialties
Gastroenterology
Orthopedics
Physiology
Top 10 Co-Authors
Tina Ho
Stephen J DiMartino
Ned Braunstein
Garen Manvelian
Paula Dakin
Haitao Gao
Gregory P Geba
Ngan Trinh
Astrid Scalori
Kenneth C Turner
Published In
BMC Musculoskelet Disord
J Hepatol
Hepatol Int
Osteoarthritis Cartilage
J Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip
DiMartino S, Gao H, Eng S, Valenzuela G, Fuerst T, Emeremni C, et al.
BMC Musculoskelet Disord . 2025 Feb; 26(1):192. PMID: 40001000
Objective: Osteoarthritis (OA) causes significant musculoskeletal pain. This study assessed the efficacy and safety of fasinumab, an investigational nerve growth factor inhibitor, in patients with moderate-to-severe OA pain of the...
2.
A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip
DiMartino S, Mei J, Schnitzer T, Gao H, Eng S, Winslow C, et al.
Osteoarthr Cartil Open . 2024 Nov; 6(4):100533. PMID: 39554479
Background: Pain associated with osteoarthritis (OA) is frequently disabling; treatments are often ineffective or intolerable. Fasinumab selectively inhibits nerve-growth factor and has shown efficacy for the management of OA pain....
3.
Prevalence of preexisting articular bone pathology in patients with osteoarthritis screened for fasinumab clinical trials identified by X-ray or magnetic resonance imaging
DiMartino S, Gao H, Neogi T, Fuerst T, Zaim S, Eng S, et al.
Osteoarthritis Cartilage . 2024 Jul; 32(12):1601-1609. PMID: 39004211
Objective: To examine the prevalence of preexisting articular bone pathology in patients with hip or knee pain due to osteoarthritis (OA) screened for fasinumab clinical trials. Method: This post-hoc analysis...
4.
Risk of carpal tunnel syndrome among patients with osteoarthritis: a US population-based study
Chen S, Ho T, Asubonteng J, Sobel R, Eng S, DiMartino S, et al.
BMC Musculoskelet Disord . 2024 Jun; 25(1):468. PMID: 38879540
Background: Carpal tunnel syndrome (CTS), an entrapment neuropathy caused by pressure of the median nerve, is a progressive condition that can lead to a decreased quality of life. Studies suggest...
5.
Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle East Respiratory Syndrome Coronavirus
Sivapalasingam S, Saviolakis G, Kulcsar K, Nakamura A, Conrad T, Hassanein M, et al.
J Infect Dis . 2021 Jan; 225(10):1765-1772. PMID: 33507266
Background: REGN3048 and REGN3051 are human monoclonal antibodies (mAb) targeting the spike glycoprotein on the Middle East respiratory syndrome coronavirus (MERS-CoV), which binds to the receptor dipeptidyl peptidase-4 (DPP4) and...
6.
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis
Gane E, Rouzier R, Hassanein T, Stedman C, Mazur W, Kupcova V, et al.
Hepatol Int . 2016 Feb; 10(3):478-87. PMID: 26886127
Background And Aim: Effective and safe antiviral treatment regimens are needed for patients with chronic hepatitis C (CHC) and cirrhosis. Methods: An international open-label trial was conducted in CHC patients...
7.
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin
Feld J, Jacobson I, Jensen D, Foster G, Pol S, Tam E, et al.
J Hepatol . 2014 Sep; 62(2):294-302. PMID: 25239078
Background & Aims: Chronic hepatitis C treatment for prior non-responders to peginterferon (PegIFN)/ribavirin remains suboptimal. The MATTERHORN study evaluated regimens containing ritonavir-boosted danoprevir (danoprevir/r) in prior PegIFN alfa/ribavirin non-responders. Methods:...